Name:
Dr Christopher Langmead FBPhS
Organisation:
Monash Institute of Pharmaceutical Sciences
Year elected:
2012
Primary professional setting:
Industry
Chris Langmead is Head of the Servier Drug Discovery Program at the Monash Institute of Pharmaceutical Sciences (MIPS); prior to this he was Head of Pharmacology at Heptares Therapeutics, a UK-based biotechnology company (2009-2012) and a neuroscience researcher at GlaxoSmithKline (1998-2009). He has a degree and PhD in pharmacology from Queens' College, Cambridge and University College London, respectively. Chris holds both commercial and NHMRC funding and is an acknowledged expert in GPCR drug discovery. He has led neuroscience projects for Parkinson’s, schizophrenia, sleep disorders and Alzheimer’s disease into late stage preclinical and early clinical development.